AbCellera Biologics Inc. (ABCL)
NASDAQ: ABCL · Real-Time Price · USD
5.20
+0.06 (1.17%)
May 22, 2026, 4:00 PM EDT - Market closed
AbCellera Biologics Stock Forecast
Stock Price Forecast
According to 9 analysts polled by S&P Global, AbCellera Biologics stock has a consensus rating of "Strong Buy" and an average price target of $10.14. The average 1-year stock price forecast is 95.00% higher than the current stock price, while the lowest is $7.00 (+34.62%) and the highest is $13 (+150.00%).
Price Target: $10.14 (+95.00%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for AbCellera Biologics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 | May '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 3 | 2 |
| Buy | 1 | 1 | 1 | 1 | 1 | 2 |
| Hold | 2 | 2 | 2 | 2 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 5 | 5 | 5 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Initiates $7 | Buy | Initiates | $7 | +34.62% | May 5, 2026 |
| Jones Trading | Jones Trading | Strong Buy Initiates $11 | Strong Buy | Initiates | $11 | +111.54% | Apr 10, 2026 |
| Leerink Partners | Leerink Partners | Buy → Hold Downgrades $4 | Buy → Hold | Downgrades | $4 | -23.08% | Nov 7, 2025 |
| Stifel | Stifel | Strong Buy Maintains $8 → $7 | Strong Buy | Maintains | $8 → $7 | +34.62% | Aug 8, 2025 |
| Keybanc | Keybanc | Buy Maintains $5 → $10 | Buy | Maintains | $5 → $10 | +92.31% | Jul 14, 2025 |
Financial Forecast
Revenue This Year
33.67M
from 75.13M
Decreased by -55.19%
Revenue Next Year
38.98M
from 33.67M
Increased by 15.78%
EPS This Year
-0.69
from -0.49
EPS Next Year
-0.73
from -0.69
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 50.4M | 70.4M | ||||||
| Avg | 33.7M | 39.0M | ||||||
| Low | 25.3M | 26.7M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | -32.9% | 109.0% | ||||||
| Avg | -55.2% | 15.8% | ||||||
| Low | -66.3% | -20.8% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | -0.62 | -0.59 | ||||||
| Avg | -0.69 | -0.73 | ||||||
| Low | -0.76 | -0.83 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
Sources: Price targets and consensus ratings provided by S&P Global Market Intelligence. Historical ratings and analyst data provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data sources.